Blueprint Medicines Corporation (BPMC)
NASDAQ: BPMC · Real-Time Price · USD
99.49
+1.98 (2.03%)
At close: May 15, 2025, 4:00 PM
99.49
0.00 (0.00%)
After-hours: May 15, 2025, 6:14 PM EDT
Blueprint Medicines Stock Forecast
Stock Price Forecast
According to 20 professional analysts, the 12-month price target for Blueprint Medicines stock ranges from a low of $76 to a high of $168. The average analyst price target of $124.05 forecasts a 24.69% increase in the stock price over the next year.
Price Target: $124.05 (+24.69%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Blueprint Medicines stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 6 | 6 | 7 | 6 | 6 |
| Buy | 7 | 7 | 7 | 8 | 8 | 8 |
| Hold | 5 | 5 | 5 | 6 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 20 | 19 | 19 | 22 | 21 | 21 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $135 | Strong Buy | Reiterates | $135 | +35.69% | May 2, 2025 |
| Needham | Needham | Strong Buy Maintains $133 → $130 | Strong Buy | Maintains | $133 → $130 | +30.67% | Apr 28, 2025 |
| Wedbush | Wedbush | Buy Reiterates $128 | Buy | Reiterates | $128 | +28.66% | Apr 16, 2025 |
| Needham | Needham | Strong Buy Reiterates $133 | Strong Buy | Reiterates | $133 | +33.68% | Apr 8, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Initiates $120 → $100 | Hold | Initiates | $120 → $100 | +0.51% | Mar 20, 2025 |
Financial Forecast
Revenue This Year
737.03M
from 508.82M
Increased by 44.85%
Revenue Next Year
973.29M
from 737.03M
Increased by 32.06%
EPS This Year
-1.19
from -1.07
EPS Next Year
1.19
from -1.19
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 854.7M | 1.1B | 1.5B | ||
| Avg | 737.0M | 973.3M | 1.2B | ||
| Low | 683.1M | 835.9M | 904.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 68.0% | 50.6% | 58.7% | ||
| Avg | 44.8% | 32.1% | 26.3% | ||
| Low | 34.2% | 13.4% | -7.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.76 | 4.11 | 7.58 | ||
| Avg | -1.19 | 1.19 | 4.04 | ||
| Low | -2.20 | -1.46 | 0.83 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 535.5% | ||
| Avg | - | - | 238.7% | ||
| Low | - | - | -30.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.